

## 12-4140: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Clone: A11) rabbit mAb PE conjugate

|                                |   |
|--------------------------------|---|
| <b>Clonality :</b>             | Monoclonal  |
| <b>Clone Name :</b>            | ERK12T202Y204-A11   |
| <b>Application :</b>           | FACS  |
| <b>Reactivity :</b>            | Human   |
| <b>Conjugate :</b>             | PE  |
| <b>Alternative Name :</b>      | Mitogen-activated protein kinase 3, MAPK3, ERK2, p44-MAPK, PRKM3, Mitogen-activated protein kinase 1, MAPK1, ERK1, p42-MAPK, PRKM1, PRKM2 |
| <b>Isotype :</b>               | Rabbit IgG1k  |
| <b>Immunogen Information :</b> | A synthetic phospho-peptide corresponding to residues surrounding Thr202/Tyr204 of human phospho Erk1/2.                                  |

### Description

Human Erk1 and Erk2 Ser/Thr kinases share 84% sequence identity and nearly all functions. These MAP kinases are activated in response to mitogens and growth factors as part of the Ras-Raf-MEK-ERK signal transduction cascade. This pathway regulates cell survival, differentiation, adhesion, cell cycle progression, and many other cellular processes. Upon phosphorylation, Erk1/2 translocate to the nucleus to activate transcription factors including c-Fos, Elk1, Ets1, and SP-1. There are more than 175 known cytoplasmic and nuclear substrates of Erk1/2. The Erk1/2 cascade is upregulated in many human cancers, even when oncogenic mutations are not found. Multiple small-molecule inhibitors of Erk1/2 have been developed, including ones targeting the ATP-binding site either competitively or irreversibly.

### Product Info

|                            |   |
|----------------------------|---|
| <b>Amount :</b>            | 10 Tests / 100 Tests                      |
| <b>Content :</b>           | 1X PBS, 0.09% NaN <sub>3</sub> , 0.2% BSA |
| <b>Storage condition :</b> | Store at 2-8°C. Do not freeze.            |

### Application Note

For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application.




Fig-1: Flow cytometric analysis of Jurkat cells, treated with U0126 and unstained as negative control (blue) or treated with U0126 and stained (red) or treated with TPA and stained (green) using Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody, ERK1/2T202/Y204-A11 PE conjugate.